The domestic biotech startup Supernova Bio announced on the 5th that it unveiled its next-generation NANO-based theranostic technology (integrating treatment and diagnostics) at the '2025 EastWest Biopharma Summit' held in Singapore on the 4th.
Supernova Bio is a biotech startup founded in September 2018 by Hanyang University Holdings and Creative Health based on the core technology of Professor Lee Geun-yong from the Department of Biotechnology at Hanyang University.
The platform unveiled by Supernova Bio on that day is characterized by its ability to physically remove target cells while monitoring the treatment process in real-time using ultrasound imaging. The company explained that it secured treatment efficiency and safety by precisely targeting tissues through a physical cell removal mechanism rather than chemical drug action.
Supernova Bio stated that it has demonstrated the effectiveness of this technology in the areas of fat reduction and cosmetic medicine through non-clinical data. It also noted that it could serve as a complementary alternative in the rapidly growing glucagon-like peptide-1 (GLP-1) anti-obesity drug market.
GLP-1 drugs are gaining attention for their systemic weight loss effects, and they are expected to grow to over $100 billion (about 146 trillion won) by 2030, but they have limitations such as muscle loss, long-term use burden, and high costs.
Lim Hyung-woo, CEO of Supernova Bio, said, "Supernova Bio's localized and non-invasive approach can complement the limitations of GLP-1," adding, "With the NANO particle platform, we can selectively remove fat cells and observe the procedure in real-time, enabling precise and safe treatment."